Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company developing losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, designed to enhance fetal hemoglobin expression for treating sickle cell disease and beta-thalassemia. These therapies aim to address the unmet medical needs of patients suffering from these debilitating genetic disorders.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Facioscapulohumeral muscular dystrophy (FSHD), sickle cell disease, and beta-thalassemia are debilitating genetic disorders with significant unmet medical needs. Current treatment options are limited and do not address the underlying causes of these diseases.
Solution
Fulcrum Therapeutics is a biopharmaceutical company focused on developing therapies for genetically defined diseases. Their lead candidate, losmapimod, is a small molecule in clinical development for FSHD, aiming to modify disease progression. Additionally, FTX-6058 is being developed to enhance fetal hemoglobin expression, offering a potential treatment for sickle cell disease and beta-thalassemia by addressing the root cause of reduced functional hemoglobin. These therapies are designed to improve the lives of patients suffering from these debilitating conditions.
Target Audience
The primary target audience includes patients suffering from facioscapulohumeral muscular dystrophy (FSHD), sickle cell disease, and beta-thalassemia, as well as the healthcare professionals who treat them.
Features
- Losmapimod: A selective p38α/β MAPK inhibitor in Phase 3 clinical trials for FSHD, designed to reduce DUX4 expression.
- FTX-6058: A small molecule designed to increase fetal hemoglobin (HbF) expression for the treatment of sickle cell disease and beta-thalassemia.
- Focus on genetically defined diseases with clear biological targets.
- Clinical-stage development programs with ongoing trials to evaluate safety and efficacy.
- Development of therapies that aim to address the underlying causes of disease, rather than just managing symptoms.